GERN vs. KDNY, ORGO, INZY, FHTX, ZIOP, EXEL, HALO, IONS, MDGL, and ALKS
Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Chinook Therapeutics (KDNY), Organogenesis (ORGO), Inozyme Pharma (INZY), Foghorn Therapeutics (FHTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "medical" sector.
Geron (NASDAQ:GERN) and Chinook Therapeutics (NASDAQ:KDNY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Geron has higher earnings, but lower revenue than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Geron currently has a consensus price target of $6.10, suggesting a potential upside of 75.79%. Chinook Therapeutics has a consensus price target of $41.00, suggesting a potential upside of 1.51%. Given Geron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Geron is more favorable than Chinook Therapeutics.
73.7% of Geron shares are held by institutional investors. Comparatively, 95.2% of Chinook Therapeutics shares are held by institutional investors. 3.1% of Geron shares are held by insiders. Comparatively, 16.8% of Chinook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Geron has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500.
Geron received 452 more outperform votes than Chinook Therapeutics when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote.
Chinook Therapeutics has a net margin of -4,199.93% compared to Geron's net margin of -38,730.00%. Chinook Therapeutics' return on equity of -58.28% beat Geron's return on equity.
In the previous week, Geron had 5 more articles in the media than Chinook Therapeutics. MarketBeat recorded 5 mentions for Geron and 0 mentions for Chinook Therapeutics. Geron's average media sentiment score of 1.22 beat Chinook Therapeutics' score of 0.67 indicating that Geron is being referred to more favorably in the media.
Summary
Geron beats Chinook Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Geron News Delivered to You Automatically
Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
